In a report released today, Jordan Abrams from Cantor Fitzgerald reiterated a Buy rating on HTG Molecular Diagnostics (HTGM), with a price target of $6. The company’s shares closed on Friday at $2.63.
Abrams noted:
“: We reiterate our Overweight rating and $6 PT on shares of HTGM. We are positive on increased visibility into the business with a focus on longer-term product development after hosting investor meetings with management last week. We think longer-term product investment positions HTG well to be the leader in RNA molecular profiling. HTG’s base profiling business remains strong (+34% in 2018) as the company continues to work with leading biopharma on biomarker identification for drug development.”
According to TipRanks.com, Abrams is ranked #4230 out of 5174 analysts.
HTG Molecular Diagnostics has an analyst consensus of Strong Buy, with a price target consensus of $6.33.
See today’s analyst top recommended stocks >>
The company has a one-year high of $5.46 and a one-year low of $2.03. Currently, HTG Molecular Diagnostics has an average volume of 332K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
HTG Molecular Diagnostics, Inc. engages in the provision of molecular technology solutions that facilitates molecular profiling. Its customers include biopharmaceutical companies, academic research centers, and molecular testing laboratories. The company was founded by Bruce E. Seligmann in October 1997 and is headquartered in Tucson, AZ.
